-
Nature Major findings: lower affinity agonist antibody is more effective
Nature重大發(fā)現(xiàn)：較低親和力激動(dòng)型抗體療效更優(yōu)長(zhǎng)期以來(lái),，研究人員將高親和力作為篩選治療性抗體的關(guān)鍵標(biāo)準(zhǔn),。目前研究中的激動(dòng)型抗體多數(shù)具有很高的親和力,，并且通過(guò)抗體的Fc功能進(jìn)行交聯(lián),，從而激活免疫細(xì)胞,，但是這些抗體在臨床中的療效甚微,，或具有較強(qiáng)的免疫不良反應(yīng),。近日,，Nature期刊上發(fā)表了題為“Reducing affinity as a strategy to boost immunomodul
2023/03/02 admin 45
-
Phase I clinical trial project of YK012 for injection was officially launched
After seven years of sharpening, the phase I clinical trial of YK012 for injection was officially launched recently.YK012 for injection is a new generation of safe, high-yield, long-acting and low-c
2023/02/07 admin 97
-
The 2022 year-end summary meeting ended successfully
On January 18, 2023, the 2022 year-end summary meeting of Ecotech (Beijing) Pharmaceutical Technology Development Co., Ltd. was held in the A101 conference room. All members of the company and the cha
2023/01/10 admin 33
-
The leaders went to the Sino-Science Life Science Industrial Park for investigation
In the afternoon of November 17, Meng Qingwu, Chairman of Yikester (Beijing) Pharmaceutical Technology Development Co., Ltd., and Qian Min, Chief Operating Officer, led a delegation to visit the Zhong
2022/11/10 admin 33
-
Fight against COVID-19 - EXCYTE is in action
"Great Xia, for the country and the people". In 2022, the epidemic was still raging. In response to the call, Yikester, Fan Shuang, Li Meiling and Wei Kun, three comrades, took the initiat
2022/01/10 admin 37
-
The application for YK012 IND, the innovative double antibody of Yikester, was approved and will enter the phase I clinical trial stage
Recently, the bispecific antibody YK012 (acceptance number: CXSL2200041) independently developed by Yikester (Beijing) Pharmaceutical Technology Development Co., Ltd. was officially approved by the Dr
2021/11/10 admin 70
